Chinook Therapeutics, Inc. (KDNY)
| Market Cap | 1.11B |
| Revenue (ttm) | 53.97M |
| Net Income (ttm) | -97.41M |
| Shares Out | 61.61M |
| EPS (ttm) | -1.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,223,560 |
| Open | 18.97 |
| Previous Close | 18.66 |
| Day's Range | 17.80 - 19.13 |
| 52-Week Range | 10.48 - 19.59 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 35.99 (+99.4%) |
| Earnings Date | Aug 11, 2022 |
About KDNY
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the t... [Read more...]
Financial Performance
In 2021, KDNY's revenue was $51.63 million, an increase of 6,142.44% compared to the previous year's $827,000. Losses were -$102.94 million, 26.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for KDNY stock is "Buy." The 12-month stock price forecast is 35.99, which is an increase of 99.39% from the latest price.
News
Wall Street Analysts See a 94% Upside in Chinook (KDNY): Can the Stock Really Move This High?
The consensus price target hints at a 93.8% upside potential for Chinook (KDNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re...
Recent Price Trend in Chinook (KDNY) is Your Friend, Here's Why
Chinook (KDNY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shor...
Does Chinook (KDNY) Have the Potential to Rally 110% as Wall Street Analysts Expect?
The mean of analysts' price targets for Chinook (KDNY) points to a 109.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to ...
Chinook Therapeutics Announces Proposed Public Offering
SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...
Chinook (KDNY) Upgraded to Buy: What Does It Mean for the Stock?
Chinook (KDNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Chinook (KDNY) Could Rally 110%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Chinook (KDNY). While the effectiveness of this highly sought-after metric is questionable, the positiv...
Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec ...
SEATTLE, May 20, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...
Chinook's Kidney Disease Candidate Continues To Show Rapid, Sustained Reductions In Biomarkers
Chinook Therapeutics Inc (NASDAQ: KDNY) announced updated interim results from the Phase 1/2 study of BION-1301 in IgA nephropathy (IgAN). IgAN, also known as Berger's disease, is a kidney disease that ...
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and...
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...
Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal As...
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...
Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...
Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibi...
SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...
Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...
Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support ...
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and technol...
Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors
SEATTLE, March 21, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...
Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...
Chinook Therapeutics to Present at Oppenheimer's 32nd Annual Healthcare Conference
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.
Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for k...
Wall Street Analysts Predict a 153% Upside in Chinook (KDNY): Here's What You Should Know
The consensus price target hints at a 152.9% upside potential for Chinook (KDNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...
Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022
SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for k...
Chinook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
SEATTLE, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for k...